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Concerns have arisen about possible effects of protease
inhibitors (PIs) on cardiac conductivity. We found no sig-
nificant association between current or recent PI exposure
and sudden death or nonhemorrhagic stroke (adjusted rate
ratio, 1.22; 95% confidence interval, .95–1.57), whereas
cumulative exposure to PIs was associated with an in-
creased risk (adjusted rate ratio, 1.06 per year of exposure;
95% confidence interval, 1.01–1.11).
Concerns have arisen about protease inhibitors (PIs) and their
potential adverse effects on cardiac conductivity, as manifested
through prolongation of QT and PR interval durations on the
standard electrocardiogram (ECG) [1]. These concerns are
largely based on case reports and small single-center studies
[2, 3]. Over the last 2 years, the Food and Drug Administration
has issued warnings that ritonavir-boosted lopinavir and rito-
navir-boosted saquinavir may cause prolongation of QTc and
PR intervals [4]. Recently, investigators from the Strategies for
Management of Antiretroviral Therapy (SMART) Study Group
reported that several PI-based regimens (whether or not boosted
with ritonavir) were associated with prolongation of the PR
interval, and average QT interval was significantly reduced
among those receiving boosted PIs compared with those receiv-
ing nonnucleoside reverse-transcriptase inhibitors (NNRTIs) [5].
Prolongation of the PR interval could be an early mani-
festation of an ongoing conduction defect that may lead to
complete AV block. Although rarely seen without other cardiac
abnormalities, one possible clinical manifestation of severe PR
interval prolongation may be congestive heart failure. Although
the associations may not be causal, it has been suggested that
prolonged PR interval may be not only a marker of AV con-
duction but also a predictor of atrial fibrillation [6] and
mortality [7]. Prolongation or shortening of the QTc interval,
which reflects issues with repolarization of myocardial cells,
predisposes the heart for torsade de pointes arrhythmia or
ventricular fibrillation with its clinical manifestation of sudden
death.
The Data Collection on Adverse Events of Anti-HIV Drugs
(D:A:D) study, a large observational multicohort collaboration
of human immunodeficiency virus (HIV)–positive individuals,
has previously reported an association between cumulative ex-
posure to the PI drug class and an increased risk of myocardial
infarction [8]. Ischemic coronary disease and some drugs used
to treat this and other related conditions may lead to abnor-
mal cardiac conductivity; sudden death due to ventricular
fibrillation is a known complication of myocardial infarction.
Sudden death and nonhemorrhagic strokes may be rare
‘‘end-stage’’ outcomes of different ECG abnormalities, for
example, prolonged QT or PR intervals. If exposure to PIs
does, indeed, cause these ECG abnormalities directly, we may
expect to see an excess risk of sudden death and non-
hemorrhagic stroke in patients currently or recently exposed
to PIs. The aim of this study was to describe associations
between current or recent exposure to the PI drug class and
the risk of sudden death or nonhemorrhagic stroke in the
D:A:D study.
METHODS
All incident cases of MI and all deaths (irrespective of cause)
are reported to the D:A:D study coordinating office for valida-
tion [8, 9]. Centrally validated cases (with cardiologist input)
of sudden deaths and nonhemorrhagic strokes were identified
using standard case definitions [10].
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Owing to the rarity of sudden death [10], our main analyses
considered associations between exposure to the PI class and
the composite end point of sudden death or the first non-
hemorrhagic stroke occurring during prospective follow-up.
Hemorrhagic strokes or strokes of unknown cause were ex-
cluded from these analyses. Follow-up was considered from
the date of D:A:D enrolment until the first of these events
(if patients experienced both events, the date of the non-
hemorrhagic stroke was taken as the end point); for patients
not experiencing one of these events, follow-up was right-
censored on the earliest of date of death from another cause,
1 February 2009, or 6 months after the last clinic visit.
We considered associations between the composite end
point and cardiovascular disease (CVD) risk factors (age, sex,
ethnicity, body mass index [BMI], smoking status, family and
personal history of CVD, hypertension [systolic blood pressure
$150 mm Hg, diastolic blood pressure $100 mm Hg, use of
ACE inhibitors, and/or antihypertensive drugs], diabetes melli-
tus, use of lipid-lowering drugs, total cholesterol, high-density
lipoprotein cholesterol, triglyceride levels), as well as HIV trans-
mission group, calendar year, and participating cohort. Variables
were categorized as in Table 1. Event rates were calculated as
the number of events divided by the total person-years of
follow-up (PYFU), and associations were described using Poisson
regression (PROC GENMOD in SAS software, version 9.1).
Reflecting our primary hypothesis that PIs may affect QT or
PR intervals which could result in sudden death, associations
were first considered with current or recent use of the PI class
(any use of PI within the past year); this definition of exposure
captures a relatively short-lived impact of the drugs on the
outcome. To allow for the possibility of other biological mech-
anisms (see Introduction), secondary analyses incorporated
cumulative exposure to PIs (ie, years of prior exposure).
PI exposure was counted regardless of whether the PI had been
boosted with ritonavir. Finally, we assessed associations with
sudden deaths alone; owing to the small number of end points,
adjustments were limited to age and previous CVD event.
RESULTS
Over the course of 234 818 PYFU, 250 of the 49 737 patients
in the D:A:D study experienced one of the events (1.06/1000
PYFU; 95% confidence interval [CI], .93–1.20). There were
78 sudden deaths (0.33/1000 PYFU; 95% CI, .26–.41) and 172
nonhemorrhagic strokes (0.73/1000 PYFU; 95% CI, .62–.84). At
the time of the event, patients experiencing either event were
more likely to be male, to have a BMI,18 kg/m2, to be smokers,
to be receiving antihypertensive medication, to have diabetes, or
to have been exposed to drugs from the NRTIs previous nu-
cleoside reverse-transcriptase inhibitor (NRTI) compared with
the remaining study population (Table 1). Patients experiencing
either end points had a greater median exposure to PIs, NRTIs,
and NNRTIs and had higher total cholesterol and triglyceride
levels than the remaining study population, whereas CD4
counts were lower in those experiencing an event.
Established CVD risk factors associated with the composite
end point were older age (adjusted rate ratio [RR] per year of
age, 1.07; 95%CI, 1.06–1.08); BMI,18 kg/m2 (2.76; 1.72–4.42),
compared with BMIs of 18–26 kg/m2; previous CVD (3.02;
2.08–4.37); current smoking (1.62; 1.13-2.32), compared
with never smoking; diabetes mellitus (1.50; 1.05–2.15); and
hypertension (1.60; 1.19–2.15). Calendar year and partici-
pating cohort were also associated with the composite end
point, although there was no clear trend to an increasing or
decreasing risk in later years. Use of lipid-lowering drugs was
not associated with the composite end point (data not
shown).
In total, 31 876 (64%) of the study group had received PIs
with a median exposure by end of follow-up of 1.50 years (in-
terquartile range, 0.00–4.82 years). Among patients currently
or recently exposed to PIs, the event rate was 1.30/1000 PYFU
(120 events/92 414 PYFU; 95% CI, 1.07–1.53), compared with
0.91/1000 PYFU (130 events/142 405 PYFU; 95% CI, .76–1.07)
for those not recently exposed to PIs. In unadjusted analyses,
those recently exposed to PIs were 42%more likely to experience
an event (unadjusted RR, 1.42; 95% CI, 1.08–1.82; P 5 .005)
than those not exposed to PIs. In an analysis that considered
cumulative exposure to the PI class, rather than recent exposure,
the RR was 1.10 per year of exposure (95% CI, 1.05–1.14;
P , .0001).
After adjustment for CVD risk factors, calendar year, and
cohort, the RR associated with recent PI exposure was attenu-
ated (adjusted RR, 1.22; 95% CI, .95–1.57; P 5 .12); the RR for
cumulative exposure was similarly attenuated (adjusted RR,
1.06; 95% CI, 1.01–1.11; P 5 .01). When both covariates were
included in the model, the adjusted RR for current or recent
PI exposure dropped further to 1.02 (95% CI, .75–1.40;
P 5 .89), whereas that for cumulative exposure was unchanged
(adjusted RR, 1.06; 1.00–1.12; P 5 .05). When the sudden
deaths alone were analyzed, RRs were similar both before
(current or recent exposure, 1.46 [95% CI, .94–2.28; P5 .09];
cumulative exposure, 1.08 [95% CI, 1.00–1.15; P 5 .04]) and
after (current or recent exposure, 1.33 [95% CI, .85–2.08;
P 5 .21]; cumulative exposure, 1.03 [95% CI, .96–1.11;
P 5 .40]) adjustment for confounders.
DISCUSSION
We did not observe an independent association between current
or recent use of PIs (as a class) and the risk of sudden death
or nonhemorrhagic stroke. Although our primary hypothesis
was that any association with PI exposure would be relatively
short lived, we did find that the risk of an event increased as
cumulative exposure increased; this association remained
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Table 1. Demographic, Cardiovascular, and HIV Characteristics of Patients in D:A:D study at Last Date of Follow-up
Variable
Composite End Point
(n 5 250)
Sudden Death
(n 5 78)
Nonhemorrhagic Stroke
(n 5 172)
D:A:D Population With No Event
at Last Follow-up (n 5 49 487)
Age, median (IQR), year 53 (45–60) 49 (42–59) 53 (47–61) 43 (37–50)
Male sex 213 (85.2) 66 (84.6) 147 (85.5) 36 339 (73.4)
Ethnicity
White 128 (51.2) 46 (59.0) 82 (47.7) 24 945 (50.4)
Black 26 (10.4) 6 (7.7) 20 (11.6) 4828 (9.8)
Other 2 (0.8) . 2 (1.2) 1392 (2.8)
Unknown 94 (37.6) 26 (33.3) 68 (39.5) 18 322 (37.0)
BMI
,18 kg/m2 21 (8.4) 4 (5.1) 17 (9.9) 1887 (3.8)
18–26 kg/m2 164 (65.6) 45 (57.7) 119 (69.2) 30 446 (61.5)
26–30 kg/m2 30 (12.0) 12 (15.4) 18 (10.5) 7140 (14.4)
.30 kg/m2 17 (6.8) 5 (6.4) 12 (7.0) 3023 (6.1)
Unknown 18 (7.2) 12 (15.4) 6 (3.5) 6991 (14.1)
Mode of infection
Homosexual 126 (50.4) 41 (52.6) 85 (49.4) 21 540 (43.5)
Heterosexual 47 (18.8) 21 (26.9) 26 (15.1) 7542 (15.2)
IDU 54 (21.6) 11 (14.1) 43 (25.0) 15 976 (32.3)
Other or unknown 23 (9.2) 5 (6.4) 18 (10.5) 4429 (9.0)
Smoking status
Current smoker 85 (34.0) 26 (33.8) 59 (34.3) 12 722 (25.7)
Former smoker 153 (61.2) 50 (65.0) 103 (59.9) 26 678 (53.9)
Family history of CVD
Yes 16 (6.4) 4 (5.2) 12 (7.0) 3179 (6.4)
No 153 (61.2) 41 (53.3) 112 (65.1) 29 411 (59.4)
Unknown 81 (32.4) 32 (41.6) 48 (27.9) 16 879 (34.1)
Previous CVD event 77 (30.8) 52 (66.7) 25 (14.5) 1248 (2.5)
Diabetes mellitus 35 (14.0) 6 (7.7) 29 (16.9) 2324 (4.7)
Hypertension 86 (34.4) 18 (23.1) 68 (39.5) 7246 (14.6)
Receipt of lipid-lowering drugs 22 (8.8) 5 (8.5) 17 (9.9) 2257 (4.6)
Coinfected with hepatitis C virus 46 (18.4) 20 (25.6) 26 (15.1) 9145 (18.)
Currently or recently exposed to ART
PIs 116 (46.4) 35 (44.9) 81 (47.1) 18 529 (37.4)
NNRTIs 86 (34.4) 27(34.6) 59 (34.3) 17 406 (35.2)
NRTIs 204 (81.6) 57 (73.1) 147 (85.5) 35 170 (71.2)
Ever exposed to ART
PIs 208 (83.2) 67 (85.9) 141 (82.0) 31 660 (64.0)
NNRTIs 159 (63.6) 50 (64.1) 109 (63.4) 29 240 (59.1)
NRTI 240 (96.0) 75 (96.2) 165 (95.9) 41 323 (83.5)
Duration of previous exposure
to ART, median (IQR), y
PIs 2.9 (0.8–5.5) 2.6 (1.1–4.9) 3.0 (0.5–6.0) 1.3 (0.0–4.6)
NNRTIs 0.8 (0.0–2.8) 0.9 (0.0–2.8) 0.8 (0.0–2.9) 0.5 (0.0–3.3)
NRTIs 6.3 (3.0–9.0) 5.7 (3.4–7.9) 6.4 (2.8–9.5) 4.5 (0.9–9.2)
Log HIV-1 RNA, median (IQR), copies/mL 1.7 (1.7–3.1) 2.6 (1.7–4.1) 1.7 (1.7–3.0) 1.7 (1.7–3.1)
CD4 count, median (IQR), cells/mm3 476 (320–664) 310 (197–539) 401 (212–615) 476 (320–644)
Lipids, median (IQR), mmol/L
TG 2.1 (1.4–3.1) 2.1 (1.4–3.1) 2.1 (1.3–3.1) 1.5 (1.0–2.4)
TC 5.2 (4.1–6.2) 5.3 (4.1–6.2) 5.2 (4.2–6.1) 4.8 (4.1–5.6)
HDL-C 1.1 (0.9–1.4) 1.0 (0.9–1.4) 1.1 (0.9–1.4) 1.2 (0.9–1.5)
Unless otherwise indicated, data represent No. (%) of subjects.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CVD, cardiovascular disease; D:A:D, Data Collection on Adverse Events of Anti-HIV Drugs; HDL-C,
high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range; NNRTIs, nonnucleoside-reverse
transcriptase inhibitors; NRTIs, nucleoside reverse-transcriptase inhibitors; PIs, protease inhibitors; TC, total cholesterol; TG, triglycerides.
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significant after adjustment for potential confounders and is
more consistent with our previously reported results indicating
that PI exposure may lead to the development of ischemic
coronary disease [9], which, in turn, may result in sudden death.
Although we did not identify a significant association with
current or recent exposure, only 250 events were observed (re-
flected in the wide CI for this association). Thus, our study is
likely to be sufficiently powered to detect only a strong signal
between current or recent exposure to the PI drug class and
the end point. Furthermore, we do not have sufficient power
to consider associations with specific PI drugs, in particular
ritonavir-boosted lopinavir and ritonavir-boosted saquinavir,
reports of which initially raised concerns with the Food and
Drug Administration [4]. Of note, data from the SMART study
suggest that associations with PIs may be class wide rather
than limited to specific PIs [5].
Owing to the expected rarity of sudden deaths [10, 11] our
primary analysis was based on a composite end point that also
incorporated nonhemorrhagic strokes. This approach makes
the assumption that any association with PI exposure is the
same for the different components of the end point. The fact
that several PIs have been reported to have an effect on the
electric conductivity of the heart means that both outcomes are
likely to be of relevance. However, because the underlying
mechanisms that link ECG abnormalities to sudden deaths and
nonhemorrhagic strokes may differ, the degree of association
with sudden death, if any, may be different from the degree
of association with nonhemorrhagic stroke. Our finding of
a higher RR for the association of current or recent PI exposure
with sudden deaths (1.33) than for the composite end point
(1.22) is consistent with this possibility. If such an association
exists, this may reflect antiretroviral drug-induced ECG ab-
normalities. If prolongation or shortening of the QTc interval
develops, this reflects issues with repolarization of myocardial cells
and may be caused by drugs that block the human ether-a`-go-go–
related gene (HERG) channels [12], which may either directly
affect the HERG-channels or indirectly cause subclinical myo-
cardial ischemia. Of interest, PIs have been shown to affect
HERG directly [2, 13]. The blocking of HERG channels has been
shown to be dose dependent for several PIs, and this suggests
that PIs could predispose to torsade de pointes [2]. Un-
fortunately, information on ECG results is not collected routinely
in the D:A:D study, and other nonfatal adverse effects of any
ECG abnormalities are not captured. Furthermore, information
on genetic predispositions that may cause prolongation of the
QTc interval are also not available.
We identified several factors (older age, previous CVD,
current smoking, diabetes, and hypertension) that were as-
sociated with an increased event rate, similar to findings in the
general population [10]. Interestingly, we found that lower
rather than higher BMI was associated with an increased risk
of the end point; the HIV-positive population has a relatively
low prevalence of obesity, and this contributes less to car-
diovascular events than other CVD risk factors. Low BMI is
strongly associated with many outcomes, possibly because it
may identify a group of patients with more advanced disease or
other comorbidities.
The study has limited information on concomitant cocaine or
methadone use or on use of antiarrythmic drugs, which may
have an impact on cardiac conductivity, although we have no
reason to believe that use of these drugs will differ according to
level of PI exposure. Finally, we are unable to distinguish sudden
deaths that result from conduction disturbances caused by
genetics from those that are secondary to ischemic heart disease.
To guide decisions regarding the routine use of ECG
screening of all patients receiving PIs, future studies are required
that consider the impact of individual PIs on the cardiac risk
profile of individual patients. Although we included follow-up
information on .49 000 patients, only 78 sudden deaths were
identified, and CIs for this end point were wide. It is very un-
likely that any other study of HIV-positive individuals with
clinical end points will collect information on sufficient sudden
deaths as an outcome. Although misclassification of sudden
deaths cannot be excluded, use of the Coding of causes of Death
(CoDe) system [14] and the evaluation of events in consultation
with a cardiologist allow us to minimize this possibility.
In conclusion, we found no evidence for an increased risk of
sudden death or nonhemorrhagic stroke among HIV-positive
individuals with recent exposure to PIs, although cumulative
exposure to PIs was associated with these outcomes. Further
analyses are planned when more end points (through extended
follow-up) have accrued.
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